Business
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
Results from pre-clinical studies conducted by scientists at Memorial Sloan Kettering Cancer Center show delayed leukemic progression and improved survival;
About this update from Launch One Acquisition Corp.
[{"type":"text","content":"Results from pre-clinical studies conducted by scientists at Memorial Sloan Kettering Cancer Center show delayed leukemic progression and improved survival; Results from Phase 1 clinical trial in Shaare Zedek Medical Center show high safety profile and preliminary efficacy\nHAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that data collected by research teams at Memorial Sloan Kettering Cancer Center (MSK) and Shaare Zedek Medical Center (SZMC) featuring the Company’s mitochondrial augmentation technology in myelodysplastic syndrome (MDS) will be presented at the 67th American Society of Hematology’s (ASH) Annual Meeting and Exposition on December 6-9, 2025 in Orlando, FL. The data will be featured in an oral presentation to be held on Saturday, Dec 6, 2PM ET (abs25-9123_abstract), as well as part of a workshop called, “Mitochondria and metabolism – clinical trials,” to be held Friday, Dec 5, 5:10PM ET. The oral presentation, to be presented by principal investigator Dr. Omar Abdel-Wahab, will outline the MSK team’s progress with Minovia’s mitochondrial augmentation technology in pre-clinical studies using an MDS animal model, as well as the SZMC team’s work studying the lead product, MNV-201, in low risk MDS patients treated in a Phase 1b clinical trial.1 To date, MNV-201 has demonstrated a high safety and tolerability profile in the seven patients receiving treatment, with no anti-mitochondrial antibodies nor drug-related adverse events. One patient experienced transfusion independence with rising hemoglobin levels that have since been sustained for more than 10 months. The same patient also demonstrated improvement in blood-based biomarkers of mitochondrial function. “The data we continue to see with our lead product, MNV-201, is encouraging, and we are grateful to the MSK nonclinical and SZMC clinical teams for spearheading the research to demonstrate its utility in this indication. We are excited by the possibility suggested by preclinical studies that mitochondrial augmentation of hematopoietic stem and progenitor cells may enable delay in disease progression to Acute Myeloid Leukemia (AML), and by the positive preliminary clinica...